Acyclic and cyclopropyl analogues of adenosine bisphosphate antagonists of the P2Y1 receptor:: Structure-activity relationships and receptor docking

被引:73
作者
Kim, HS
Barak, D
Harden, TK
Boyer, JL
Jacobson, KA
机构
[1] NIDDK, Mol Recognit Sect, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA
[2] Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA
关键词
D O I
10.1021/jm010082h
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The activation of P2Y(1) receptors in platelets contributes to platelet aggregation, and selective antagonists are sought as potential antithrombotic agents. We reported (Kim et al. J. bled. Chem. 2000, 43, 746-755) that acyclic analogues of adenine nucleotides, containing two phosphate groups on a symmetrically branched aliphatic chain, attached at the 9-position of adenine, are moderately potent P2Y(1) receptor antagonists. In this study we have varied the chain structure, to include asymmetric substitution, olefinic, and cyclopropyl groups. These antagonists inhibited the stimulation of phospholipase C in turkey erythrocyte membranes induced by 30 nM 2-MeS-ADP in the micromolar range. In the series of symmetrically branched aliphatic groups substituted with two phosphate groups, the optimal antagonist potency occurred with the 2-methylpropyl group. A 2-chloro-N-6-methyladenine derivative, 2-[2-(2-chloro-6-methylaminopurin-9-yl)methyl]propane-1,3-bisoxy(diammoniumphosphate) (7), was a full antagonist at the P2Y(1) receptor with an IC50 value of 0.48 muM. Esterification of one of the phosphate groups or substitution with O-acetyl greatly reduced the antagonist potency at the P2Y(1) receptor. Removal of a methylene group of 7 or inclusion of an olefinic or cyclopropyl group also reduced potency. A pair of enantiomeric glycerol derivatives demonstrated a 5-fold stereoselectivity for the S-isomer. Stereoisomerically defined analogues of 7 containing a cyclopropyl group in place of the branched carbon were less potent than 7 as antagonists, with IC50 values of 2-3 muM. No agonist activity was observed for these analogues. A new rhodopsin-based molecular model of the P2Y(1) receptor indicated that the optimal docked orientation of the two monophosphate moieties relative to the adenine N-6 (compared to a rigid, bicyclic analogue) was consistent with the dependence of antagonist potency on chain length. The 3 ' -phosphate was predicted to occupy a restricted space, deeper in the binding cleft than the 5 ' -phosphate location. In summary, modification of the flexible spacer chain linking bisphosphate groups to the adenine moiety provided many moderately potent antagonists.
引用
收藏
页码:3092 / 3108
页数:17
相关论文
共 38 条
[1]  
Boyer JL, 1996, MOL PHARMACOL, V50, P1323
[2]   Competitive and selective antagonism of P2Y1 receptors by N6-methyl 2′-deoxyadenosine 3′,5′-bisphosphate [J].
Boyer, JL ;
Mohanram, A ;
Camaioni, E ;
Jacobson, KA ;
Harden, TK .
BRITISH JOURNAL OF PHARMACOLOGY, 1998, 124 (01) :1-3
[3]  
BOYER JL, 1989, J BIOL CHEM, V264, P884
[4]  
BOYER JL, 2000, DRUG DEV RES S, V50, P21
[5]  
Brown SG, 2000, DRUG DEVELOP RES, V49, P253
[6]  
Burnstock G, 2000, J PHARMACOL EXP THER, V295, P862
[7]   Deoxyadenosine bisphosphate derivatives as potent antagonists at P2Y1 receptors [J].
Camaioni, E ;
Boyer, JL ;
Mohanram, A ;
Harden, TK ;
Jacobson, KA .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (02) :183-190
[8]   Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice [J].
Fabre, JE ;
Nguyen, MT ;
Latour, A ;
Keifer, JA ;
Audoly, LP ;
Coffman, TM ;
Koller, BH .
NATURE MEDICINE, 1999, 5 (10) :1199-1202
[9]  
FILTZ TM, 1994, MOL PHARMACOL, V46, P8
[10]   Towards a revised nomenclature for P1 and P2 receptors [J].
Fredholm, BB ;
Abbracchio, MP ;
Burnstock, G ;
Dubyak, GR ;
Harden, TK ;
Jacobson, KA ;
Schwabe, U ;
Williams, M .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1997, 18 (03) :79-82